|
A US listing for the oncology specialist continues a bumper year for biotech IPOs.
|
 |
|
The regulatory decision followed findings from PRIOH-1 Part C, an open-label, comparator-controlled Phase III superiority trial.
|
|
|
Perceptive and Nucleus will direct qualified customer opportunities to the other across the development pipeline.
|
|
|
Tecentriq is now the first immunotherapy indicated for dMMR colon cancer treatment specifically, which is often linked to a higher risk of progression after surgery.
|
|
|
The transaction grants Ono exclusive rights for candidates BHV-1300, BHV-1310, and BHV-1320 across Taiwan, South Korea, and Japan.
|
|
